Market Overview

UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results

Related RIGL
What You Need to Know About the Roche-InterMune Deal
InterMune's Roche Deal Sends Peer Group Up

Jefferies reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but lowered its price target from $21 to $15.

Jefferies noted, "RIGL announced OSKIRA-4 results in which fostamatinib monotherapy failed to show non-inferiority to Humira. In a separate analysis, higher dose regimens of fostamatinib showed superiority against placebo. With $3 in year-end cash and $2 in cash approval milestones if fostamatanib can be approved, we believe the selloff reflects an overly negative Street view on fostamatinib prospects and would be a buyer."

Rigel Pharmaceuticals closed at $8.43 on Wednesday.

Latest Ratings for RIGL

DateFirmActionFromTo
Mar 2014JefferiesMaintainsBuy
Jun 2013JefferiesMaintainsBuy
Jun 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters